Nasdaq · CIK 0001359931
TARA Protara Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 27, 2026. Close $2.76 on Oct 9, 2026, +8% from the 52-week low and -64% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
TARAOct 9, 2026 · close 2.76
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Protara Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Richard S Levy director buy | $64k 20,000 shares | +65% | - | |
| 33Weak | Richard S Levy director buy | $64k 20,000 shares | +65% | - |
Transactions
The last 46 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | Hannah Fry VP, Controller | FTax withholding Common Stock | -1,457 | $6.67 | $9,718 | 42,723 | Jan 27, 2026 |
| Jan 26, 2026 | Jacqueline Zummo Chf Scientific Operations Off | FTax withholding Common Stock | -3,724 | $6.67 | $25k | 118,559 | Jan 27, 2026 |
| Jan 26, 2026 | Jesse Shefferman CEO and President | FTax withholding Common Stock | -8,732 | $6.67 | $58k | 1,021,832 | Jan 27, 2026 |
| Jan 26, 2026 | Patrick Fabbio Chief Financial Officer | FTax withholding Common Stock | -3,261 | $6.67 | $22k | 64,115 | Jan 27, 2026 |
| Jan 20, 2026 | Patrick Fabbio Chief Financial Officer | FTax withholding Common Stock | -3,063 | $5.60 | $17k | 67,376 | Jan 22, 2026 |
| Jan 20, 2026 | Hannah Fry VP, Controller | FTax withholding Common Stock | -2,132 | $5.60 | $12k | 44,180 | Jan 22, 2026 |
| Jan 20, 2026 | Jacqueline Zummo Chf Scientific Operations Off | FTax withholding Common Stock | -6,578 | $5.60 | $37k | 122,283 | Jan 22, 2026 |
| Jan 20, 2026 | Jesse Shefferman CEO and President | FTax withholding Common Stock | -16,322 | $5.60 | $91k | 1,030,564 | Jan 22, 2026 |
| Jan 16, 2026 | Jacqueline Zummo Chf Scientific Operations Off | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 128,861 | Jan 21, 2026 |
| Jan 16, 2026 | Leonardo Viana Nicacio Chief Medical Officer | AGrant or award Common Stock | +26,000 | $0.00 | $0 | 78,181 | Jan 21, 2026 |
| Jan 16, 2026 | Jesse Shefferman CEO and President | AGrant or award Common Stock | +87,000 | $0.00 | $0 | 1,046,886 | Jan 21, 2026 |
| Jan 16, 2026 | Hannah Fry VP, Controller | AGrant or award Common Stock | +9,500 | $0.00 | $0 | 46,312 | Jan 21, 2026 |
| Jan 16, 2026 | Patrick Fabbio Chief Financial Officer | AGrant or award Common Stock | +28,000 | $0.00 | $0 | 70,439 | Jan 21, 2026 |
| Jan 16, 2026 | William Conkling Chief Commercial Officer | AGrant or award Common Stock | +26,000 | $0.00 | $0 | 76,000 | Jan 21, 2026 |
| Jan 16, 2026 | Jesse Shefferman CEO and President | AGrant or award Stock Option (Right to Buy)derivative | +524,000 | $0.00 | $0 | 524,000 | Jan 21, 2026 |
| Jan 16, 2026 | Jacqueline Zummo Chf Scientific Operations Off | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Jan 21, 2026 |
| Jan 16, 2026 | Patrick Fabbio Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 21, 2026 |
| Jan 16, 2026 | Leonardo Viana Nicacio Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +158,000 | $0.00 | $0 | 158,000 | Jan 21, 2026 |
| Jan 16, 2026 | Hannah Fry VP, Controller | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jan 21, 2026 |
| Jan 16, 2026 | William Conkling Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +158,000 | $0.00 | $0 | 158,000 | Jan 21, 2026 |
| Jun 24, 2025 | Jesse Shefferman CEO and President | GGift Common Stock | -300,000 | $0.00 | $0 | 659,886 | Jul 7, 2025 |
| Jun 26, 2025 | Jesse Shefferman CEO and President | GGift Common Stock | -1,700 | $0.00 | $0 | 976,853 | Jun 30, 2025 |
| Jun 26, 2025 | Jesse Shefferman CEO and President | GGift Common Stock | -3,400 | $0.00 | $0 | 973,453 | Jun 30, 2025 |
| Jun 27, 2025 | Jesse Shefferman CEO and President | GGift Common Stock | -10,200 | $0.00 | $0 | 963,253 | Jun 30, 2025 |
| Jun 27, 2025 | Jesse Shefferman CEO and President | GGift Common Stock | -3,367 | $0.00 | $0 | 959,886 | Jun 30, 2025 |
| Jun 12, 2025 | Luke M Beshar director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Barry P Flannelly director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Roger Garceau director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Jane Huang director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Richard S Levy director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Gregory Sargen director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Cynthia Smith director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 12, 2025 | Michael Edward Solomon director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 2, 2025 | William Conkling Chief Commercial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2025 |
| Jun 2, 2025 | William Conkling Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jun 4, 2025 |
| May 14, 2025 | Richard S Levy director | POpen-market purchase Common Stock | +20,000 | $3.19 | $64k | 51,000 | May 19, 2025 |
| May 14, 2025 | Richard S Levy director | POpen-market purchase Common Stock | +20,000 | $3.19 | $64k | 51,000 | May 16, 2025 |
| Apr 15, 2025 | Leonardo Viana Nicacio Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 52,181 | Apr 17, 2025 |
| Apr 15, 2025 | Leonardo Viana Nicacio Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Apr 17, 2025 |
| Jan 24, 2025 | Patrick Fabbio Chief Financial Officer | AGrant or award Common Stock | +23,500 | $0.00 | $0 | 45,500 | Jan 28, 2025 |
| Jan 24, 2025 | Hannah Fry VP, Controller | AGrant or award Common Stock | +9,500 | $0.00 | $0 | 38,942 | Jan 28, 2025 |
| Jan 24, 2025 | Patrick Fabbio Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Jan 28, 2025 |
| Jan 24, 2025 | Hannah Fry VP, Controller | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jan 28, 2025 |
| Jan 21, 2025 | Patrick Fabbio Chief Financial Officer | FTax withholding Common Stock | -3,061 | $4.76 | $15k | 18,939 | Jan 23, 2025 |
| Jan 21, 2025 | Hannah Fry VP, Controller | FTax withholding Common Stock | -2,130 | $4.76 | $10k | 27,312 | Jan 23, 2025 |
| Jan 3, 2025 | Hannah Fry VP, Controller | FTax withholding Common Stock | -394 | $6.14 | $2,419 | 29,442 | Jan 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Luke M Beshardirector
- William ConklingChief Commercial Officer
- Patrick FabbioChief Financial Officer
- Barry P Flannellyofficer, director
- Hannah FryVP, Controller
- Roger Garceaudirector
- Jane Huangpresident, officer, director
- Richard S Levydirector
- Leonardo Viana NicacioChief Medical Officer
- Gregory Sargendirector
- Jesse SheffermanCEO and President
- Cynthia Smithdirector
- Michael Edward Solomondirector
- Jacqueline ZummoChf Scientific Operations Off
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.